Our objective was to explore and create a taxonomy for access barriers by using the case study of tumor necrosis factor (TNF) alpha inhibitors (a group of active compounds where biosimilars are also available) in RA as an illustrative example based on the experience from 5 CEE countries. This evidence concerns the gene TNF and rheumatoid arthritis.